Promising Prospects for Cingulate Inc.: Buy Rating Backed by Positive Phase 3 Results and Market Potential of CTx-1301

In a report released yesterday, Naz Rahman from Maxim Group reiterated a Buy rating on Cingulate Inc (CING – Research Report), with a price target of $8.00.

Naz Rahman has given his Buy rating due to a combination of factors that highlight the promising prospects of Cingulate Inc. The company recently announced positive safety results from its Phase 3 and Fed/Fast studies for CTx-1301, a treatment for ADHD, which showed no material adverse effects and demonstrated a strong safety profile. This paves the way for an NDA submission in mid-2025, with an FDA meeting already scheduled for early April 2025.
CTx-1301 has shown potential best-in-class onset and duration, which is particularly advantageous given the current stimulant shortages. The drug’s ability to provide a quick onset and last throughout the active day, while reducing the pill burden to a single dose, positions it as a competitive differentiator in the market. Additionally, the valuation model applied by Rahman forecasts a launch in 2027, with a calculated 12-month price target of $8.00, reflecting the potential commercial success of CTx-1301.

In another report released today, Roth MKM also maintained a Buy rating on the stock with a $12.00 price target.

CING’s price has also changed dramatically for the past six months – from $6.710 to $3.850, which is a -42.62% drop .